MERCK-MILLIPORE
Merck Millipore, the Life Science division of Merck, announced it has received two R&D Magazine 100 Awards for innovative products released to market in 2014. The 52nd Annual R&D Awards recognize the 100 most technologically significant products introduced into the marketplace over the past year.
“A key component of our strategy is to offer the highest quality and most innovative products. Recognition for two R&D Magazine awards exemplifies our technical expertise and leadership in providing differentiated solutions to a broad range of customers across the life science industry,” said Udit Batra, President and Chief Executive Officer of Merck Millipore. “In 2013, Merck Millipore invested €160 million in R&D activities, and we will continue to support efforts to drive future advancements in our portfolio of offerings. We are most appreciative of those employees who have dedicated their careers to furthering scientific advancement in these fields.”
The Merck Millipore products that were recognized are:
- The SmartFlare™ detection reagent is a novel probe capable of detecting specific mRNAs and miRNAs in live, intact cells. This technology allows for carrier-free cellular endocytosis of the reagent, followed by detection and relative quantitative analysis of RNA levels. Because the reagent leaves the cell after the detection event, the same sample can be used for any downstream analysis, meaning you can assess multiple biomarkers or downstream functionalities in the same cells.
- Clarisolve ® depth filters are specifically tuned to the particle size distribution of various pretreatment methodologies enabling the fastest and most efficient way to clarify high-density streams and easily transfer processes from upstream to downstream without the use of centrifugation. Clarisolve depth filters were designed for high cell density/titer mammalian cell culture feed streams for mAb production. There has also been early success in microbial and vaccine applications.
With nearly 800 employees focused on R&D, Merck Millipore is working with customers to develop innovative solutions for the research, development and production of biopharmaceuticals and biotech processes worldwide.
Widely regarded as the “Oscars of Invention”, the R&D 100 Awards identify and celebrate the top technology products of the year. Past winners have included sophisticated testing equipment, innovative new materials, chemistry breakthroughs, biomedical products, consumer items, and high-energy physics. The R&D 100 Awards spans industry, academia, and government-sponsored research.
The winners of the R&D 100 Awards are selected by an independent judging panel and the editors of R&D Magazine.
About Merck Millipore
Merck Millipore is the Life Science
division of Merck and offers a broad range of innovative, performance
products, services and business relationships that enable our customers’
success in research, development and production of biotech and
pharmaceutical drug therapies. Through dedicated collaboration on new
scientific and engineering insights, and as one of the top three R&D
investors in the Life Science Tools industry, Merck Millipore serves as
a strategic partner to customers and helps advance the promise of life
science. Headquartered in Billerica, Massachusetts, the division has
around 10,000 employees, operations in 66 countries and 2013 revenues of
€2.6 billion Merck Millipore operates as EMD Millipore in the U.S. and
Canada.
About Merck
Merck is a leading company for innovative and
top-quality high-tech products in the pharmaceutical and chemical
sectors. With its four divisions Merck Serono, Consumer Health,
Performance Materials and Merck Millipore, Merck generated total
revenues of €11.1 billion in 2013. Around 39,000 Merck employees work in
66 countries to improve the quality of life for patients, to further the
success of customers and to help meet global challenges. Merck is the
world’s oldest pharmaceutical and chemical company – since 1668, the
company has stood for innovation, business success and responsible
entrepreneurship. Holding an approximately 70 percent interest, the
founding family remains the majority owner of the company to this day.
Merck, Darmstadt, Germany is holding the global rights to the Merck name
and brand. The only exceptions are Canada and the United States, where
the company is known as EMD.
About R&D Magazine
Since its founding in 1959 as Industrial
Research
, R&D Magazine
has served research
scientists, engineers and technical staff at laboratories around the
world, providing timely, informative news and useful technical articles
that broaden readers’ knowledge of the research and development industry
and improve the quality of their work. R&D Magazine
is a
publication of Advantage Business Media (www.advantagebusinessmedia.com
).
Contact:
Susan Alesina, 978-715-4622
susan.alesina@emdmillipore.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release
Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release
Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release
New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum